JP Morgan Chase
ALDX icon

JP Morgan Chase’s Aldeyra Therapeutics ALDX Stock Holding History

JP Morgan Chase’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$38.9K Buy
23,158
+1,169
+5% +$5.12K ﹤0.01% 6298
2025
Q4 		$114K Sell
21,989
-5,133
-19% -$26.4K ﹤0.01% 5818
2025
Q3 		$142K Buy
27,122
+1,418
+6% +$7.39K ﹤0.01% 5721
2025
Q2 		$98.4K Sell
25,704
-1,840
-7% -$4.76K ﹤0.01% 5617
2025
Q1 		$158K Buy
27,544
+2,150
+8% +$12.7K ﹤0.01% 5347
2024
Q4 		$127K Buy
25,394
+1,578
+7% +$8.1K ﹤0.01% 5660
2024
Q3 		$128K Buy
23,816
+1,883
+9% +$8.96K ﹤0.01% 5592
2024
Q2 		$72.6K Buy
21,933
+2,492
+13% +$9.76K ﹤0.01% 5691
2024
Q1 		$63.6K Sell
19,441
-12,238
-39% -$40.3K ﹤0.01% 5848
2023
Q4 		$111K Sell
31,679
-248
-0.8% -$765 ﹤0.01% 5691
2023
Q3 		$213K Sell
31,927
-4,504
-12% -$33.4K ﹤0.01% 5035
2023
Q2 		$306K Buy
36,431
+36,358
+49,805% +$358K ﹤0.01% 4813
2023
Q1 		$1K Hold
73
– – ﹤0.01% 6485
2022
Q4 		$1K Sell
73
-20
-22% -$114 ﹤0.01% 6371
2022
Q3 		$0 Buy
93
+20
+27% +$120 ﹤0.01% 6430
2022
Q2 		$0 Sell
73
-22,762
-100% -$78.3K ﹤0.01% 6431
2022
Q1 		$101K Buy
22,835
+4,012
+21% +$16K ﹤0.01% 5504
2021
Q4 		$75K Buy
18,823
+832
+5% +$6.34K ﹤0.01% 5787
2021
Q3 		$158K Sell
17,991
-679
-4% -$6.23K ﹤0.01% 5354
2021
Q2 		$211K Buy
18,670
+18,622
+38,796% +$224K ﹤0.01% 5218
2021
Q1 		$1K Hold
48
– – ﹤0.01% 5962
2020
Q4 		$0 Hold
48
– – ﹤0.01% 5601
2020
Q3 		$0 Sell
48
-3,381
-99% -$21.8K ﹤0.01% 5450
2020
Q2 		$14K Sell
3,429
-59,911
-95% -$219K ﹤0.01% 5083
2020
Q1 		$156K Buy
63,340
+55,946
+757% +$252K ﹤0.01% 4368
2019
Q4 		$43K Sell
7,394
-26,929
-78% -$156K ﹤0.01% 5172
2019
Q3 		$181K Buy
34,323
+28,128
+454% +$151K ﹤0.01% 4678
2019
Q2 		$38K Buy
6,195
+1,041
+20% +$7.83K ﹤0.01% 5276
2019
Q1 		$47K Sell
5,154
-18,866
-79% -$160K ﹤0.01% 5157
2018
Q4 		$200K Buy
24,020
+16,799
+233% +$172K ﹤0.01% 4601
2018
Q3 		$99K Sell
7,221
-56,075
-89% -$455K ﹤0.01% 4953
2018
Q2 		$503K Buy
63,296
+3,794
+6% +$30.3K ﹤0.01% 4175
2018
Q1 		$446K Buy
59,502
+9,826
+20% +$74.6K ﹤0.01% 4063
2017
Q4 		$338K Buy
+49,676
New +$327K ﹤0.01% 4241
2017
Q2 		– Sell
-1,100
Closed -$6K – 4933
2017
Q1 		$6K Buy
+1,100
New +$5.66K ﹤0.01% 4870
2016
Q4 		– Sell
-1,400
Closed -$11K – 4988
2016
Q3 		$11K Buy
1,400
+1,200
+600% +$7.33K ﹤0.01% 4277
2016
Q2 		$1K Buy
+200
New +$1.12K ﹤0.01% 4652
2015
Q4 		– Sell
-63,605
Closed -$371K – 4672
2015
Q3 		$371K Buy
+63,605
New +$497K ﹤0.01% 3524

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JP Morgan Chase's ALDX Position: Q1 2026 in Review

JP Morgan Chase increased its Aldeyra Therapeutics (ALDX) stake by 5.3% in Q1 2026, buying an estimated $5.12K and bringing the position to 23,158 shares worth $38.9K. The position accounts for ﹤0.01% of the portfolio, ranked #6298.

JP Morgan Chase first reported a position in ALDX in Q3 2015 and has held it in 38 quarters since. The position peaked at $503K in Q2 2018. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

  • JP Morgan Chase held 23,158 shares of Aldeyra Therapeutics worth $38.9K as of Q1 2026.
  • JP Morgan Chase bought 1,169 Aldeyra Therapeutics shares in Q1 2026, an estimated $5.12K.
  • Aldeyra Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #6298 holding.
  • JP Morgan Chase first reported a position in Aldeyra Therapeutics in Q3 2015 and has held it in 38 quarters since.
  • JP Morgan Chase's Aldeyra Therapeutics position peaked at $503K in Q2 2018.
  • 126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.